Resumen
Recombinant human bone morphogenetic proteins (rhBMPs) have been extensively investigated for developing therapeutic strategies aimed at the restoration and treatment of orthopaedic as well as craniofacial conditions. In this first part of the review, we discuss the rationale for the necessary use of carrier systems to deliver rhBMP-2 and rhBMP-7 to sites of bone tissue regeneration and repair. General requirements for growth factor delivery systems emphasizing the distinction between localized and release-controlled delivery strategies are presented highlighting the current limitations in the development of an effective rhBMP delivery system applicable in clinical bone tissue engineering.
Idioma original | Inglés |
---|---|
Páginas (desde-hasta) | 1817-1824 |
Número de páginas | 8 |
Publicación | Biotechnology Letters |
Volumen | 31 |
N.º | 12 |
Fecha en línea anticipada | 19 ago. 2009 |
DOI | |
Estado | Publicada - nov. 2009 |
Publicado de forma externa | Sí |